Axogen, Inc. (AXGN)
| Market Cap | 2.18B |
| Revenue (ttm) | 238.11M |
| Net Income (ttm) | -31.45M |
| Shares Out | 51.90M |
| EPS (ttm) | -0.67 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,917,817 |
| Open | 43.00 |
| Previous Close | 39.39 |
| Day's Range | 41.48 - 45.83 |
| 52-Week Range | 9.22 - 45.83 |
| Beta | 0.98 |
| Analysts | Strong Buy |
| Price Target | 39.25 (-6.57%) |
| Earnings Date | Apr 28, 2026 |
About AXGN
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstr... [Read more]
Financial Performance
In 2025, Axogen's revenue was $225.21 million, an increase of 20.21% compared to the previous year's $187.34 million. Losses were -$15.70 million, 57.6% more than in 2024.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for AXGN stock is "Strong Buy." The 12-month stock price target is $39.25, which is a decrease of -6.57% from the latest price.
News
Axogen Earnings Call Transcript: Q1 2026
Revenue grew 26.6% year-over-year to $61.5M in Q1 2026, with strong double-digit growth across all markets and expanded commercial coverage. Full-year guidance was raised to at least $270M revenue and 74%-76% gross margin, with continued investment in sales force and innovation.
Axogen, Inc. Reports First Quarter 2026 Financial Results
ALACHUA, Fla. and TAMPA, Fla.
Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026
ALACHUA, Fla. and TAMPA, Fla.
Axogen Transcript: The Citizens Life Sciences Conference 2026
Achieved broad BLA label and 12 years of exclusivity, enabling continued market leadership in nerve care. Insurance coverage is expanding, with all technical requirements met for major payers, and CMS reimbursement has improved. Growth strategies focus on education, targeted accounts, and expanding the sales force.
Axogen Transcript: Leerink Global Healthcare Conference 2026
Validated business models and double-digit growth across all segments are driving expansion, with a strengthened balance sheet and at least 18% top-line growth targeted for 2026. Regulatory milestones and reimbursement wins set the stage for operational efficiencies and broader market access.
Axogen Transcript: 47th Annual Raymond James Institutional Investor Conference
Focused on making peripheral nerve restoration a standard of care, the company targets growth in extremities, breast, and oral maxillofacial markets, with prostate care in development. Recent BLA approval for AVANCE supports payer coverage and operational improvements, while strong financials and a recent capital raise position the company for continued expansion.
Axogen Earnings Call Transcript: Q4 2025
Revenue grew 20% year-over-year with strong double-digit growth across all markets and a key FDA BLA approval for Avance. 2026 guidance targets at least 18% revenue growth, with gross margin stability and continued investment in commercial and R&D initiatives.
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
ALACHUA, Fla. and TAMPA, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera...
Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
ALACHUA, Fla. and TAMPA, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera...
Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock
ALACHUA, Fla. and TAMPA, Fla.
Axogen Announces Proposed Public Offering of Common Stock
ALACHUA, Fla. and TAMPA, Fla.
Axogen Transcript: 44th Annual J.P. Morgan Healthcare Conference
The presentation highlighted a clear strategic focus on expanding peripheral nerve care, leveraging the recent BLA approval for Avance to drive growth, improve margins, and enhance reimbursement. High double-digit growth is expected in elective markets, with new clinical pathways and international expansion under evaluation.
Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025
ALACHUA, Fla. and TAMPA, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera...
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
ALACHUA, Fla. and TAMPA, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical technologies for the restoration of periph...
FDA approves Axogen's nerve repair graft
The U.S. Food and Drug Administration has approved Axogen's nerve repair graft, the health regulator said on Wednesday.
Axogen Transcript: Piper Sandler 37th Annual Healthcare Conference
A leading innovator in nerve repair aims to set new standards of care with unique allograft products and a robust clinical portfolio, targeting 15%-20% annual growth and global expansion. Recent reimbursement improvements and strong clinical evidence support continued adoption.
Axogen Transcript: Jefferies London Healthcare Conference 2025
The session highlighted a strong growth outlook driven by expanding clinical guidelines, payer coverage, and a stratified salesforce. BLA approval is expected by December 5, unlocking operational efficiencies and reinforcing market leadership. Gross margins are projected to remain above 75%.
Axogen Earnings Call Transcript: Q3 2025
Q3 2025 saw 23.5% revenue growth, strong gross margin, and net income improvement, driven by Avance Nerve Graft adoption and expanded payer coverage. BLA approval for Avance is expected by December, securing market exclusivity and supporting further growth.
Axogen, Inc. Reports Third Quarter 2025 Financial Results
Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million
Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN
LOS ANGELES--(BUSINESS WIRE)--Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN.
AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $AXGN--AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm.
Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft
ALACHUA, Fla. and TAMPA, Fla.
Axogen Earnings Call Transcript: Q2 2025
Q2 2025 revenue grew 18.3% year-over-year to $56.7 million, driven by strong adoption across all target markets and high-potential accounts. Gross margin improved to 74.2%, and full-year revenue guidance was raised to at least 17% growth, with BLA approval for Avance Nerve Graft on track for September.
Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference
ALACHUA, Fla. and TAMPA, Fla., July 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera...
Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025
ALACHUA, Fla. and TAMPA, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera...